Orphagen Seeks Ligands for Orphan Nuclear Receptors
By Trista Morrison
Wednesday, August 8, 2012
Orphagen Pharmaceuticals Inc. knows its orphan nuclear receptor programs are too early stage for most venture capitalists. In fact, they're too early even for most academics, CEO Scott Thacher told BioWorld Today.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.